Avgol, a global leader in the manufacture of high performance nonwoven fabric solutions, has been shortlisted for an industry-renowned HYGIENIX Innovation Award™ for its advanced antimicrobial solution, beneFIT™Control.
beneFIT Control is a tailored ‘next-generation’ antimicrobial solution developed to aid in contamination, discomfort and odour by controlling the microbial activity within hygiene applications, including diapers, adult incontinence products and feminine care. The adaptable, favorably colored solution maximizes the effect on troublesome organisms and has a unique, groundbreaking ability to minimize the impact on natural and normal skin flora and the environment after disposal.
Nick Carter, Director Market Business Intelligence and Intellectual Property, at Avgol, said: “At Avgol we are passionate about developing visionary products and solutions that deliver relevant, timely and tangible value to our customers. This is why we are driving forward with our Forward Innovative Thinking (‘FIT’) strategy to deliver high-performance technologies to anticipate the needs of the baby diaper, adult incontinence and feminine hygiene markets.
“It is extremely gratifying to be recognised in these industry-renowned awards and I would like to thank every member of the Avgol team for their hard work in bringing beneFIT Control to market.”
Held annually, the HYGIENIX Innovation Awards recognise innovation within the entire disposable absorbent hygiene value chain that utilises nonwoven fabric or technology in a way that expands the usage of nonwovens. The winners will be announced during the annual HYGIENIX Conference, this year held November 5-8 at the Loews Portofino Bay Hotel in Orlando, Florida, USA.
beneFIT Control is part of the beneFIT family of functional skin wellness technologies, a new range of chemistries and processes developed by Avgol to deliver superior performance and comfort to consumers. beneFIT Control can be used in tandem with other of Avgol’s FIT technologies to enhance functionality even further.